4//SEC Filing
Turtle Cameron 4
Accession 0001758363-25-000003
CIK 0001636282other
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 9:52 PM ET
Size
7.5 KB
Accession
0001758363-25-000003
Insider Transaction Report
Form 4
Turtle Cameron
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-12-01$28.73/sh−10,995$315,886→ 690,912 total - Sale
Common Stock
2025-12-01$29.83/sh−4,005$119,469→ 686,907 total
Footnotes (4)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.45 to $29.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Includes 174,228 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date.
- [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.47 to $30.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Documents
Issuer
Spyre Therapeutics, Inc.
CIK 0001636282
Entity typeother
Related Parties
1- filerCIK 0001758363
Filing Metadata
- Form type
- 4
- Filed
- Dec 2, 7:00 PM ET
- Accepted
- Dec 3, 9:52 PM ET
- Size
- 7.5 KB